Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-24714 in advanced solid tumors
NCT05381909Phase 1Terminated
- Sponsor
- BeiGene
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Countries
- 5
01
Overview
Phase 1, open-label trial of BGB-24714 in solid tumor, non-small cell lung cancer (NSCLC) and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Primary endpoints: Number of participants with adverse events at 6 months, Maximum tolerated dose at 6 months and 2 more. Started Jul 2022; status: terminated.
02
Drugs
BGB-24714
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05381909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381909.